For the first time since the pandemic started, we are pleased to announce that the 22nd Annual Biotech in Europe Forum (BEF) will take place In-Person on the 21st-22nd of September 2022 at the Mövenpick Hotel Basel. The event will be part of the Sachs Autumn Life Sciences Week, which will also incorporate the 9th Annual HealthTech Investment Forum.
The physical programme will consist of the usual panels and keynotes, which will be available on demand the week after. Additionally, there will be pre-arranged in-person meetings, live and on demand company showcases and a reception. The in-person event will be followed by an additional week of virtual meetings available through the audio/video online meeting system.
Back for its 22nd Annual Edition, this global bio-pharma industry event will address through its programme the main challenges in investment for 2022, partnering and alliance management and prospects for 2023. Key players contribute their insights in panels which cover the macro picture as well as innovation in different therapeutic sectors. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners.
The main programme for the 22nd Annual BEF is spread throughout 2 days (21st – 22nd of September) and will feature more than 15 hours of high-level keynotes and panel discussions. In addition, there will be a global company showcase of 50+ presentations by established public, private, emerging and seed companies, offering innovative solutions and seeking investment and partnering opportunities. This will include a limited number of live presentations taking place in dedicated presentation tracks, alongside virtual company showcases, which will be available on demand during the virtual week. We anticipate 650+ delegates will register for the forum from all Life Sciences sectors, with the target audience being corporate and financial investors/partners, banks and advisors with part of the audience participating virtually.
The In-Person meetings will be taking place on the 21st – 22nd of September, while virtual meetings will take place on the 26th – 30th of September. For the virtual meetings, the system will allow you to have a secure audio/video call, as well as option to present slides using a screen share function and we will have a dedicated room for in-person meetings. We expect 1000+ meetings completed during SALSW. The conference will be held in the Central European Time Zone. The programme will consist of:
Day 1 (Wednesday, 21st of September)
- State of the Industry Panel
- VC & Private Equity Roundtable
- Advances in Platform Technologies & Novel Therapeutics Panel
- Investing in Gene & Cell Therapy Companies Panel
- American Capital Markets Panel
- Immuno-Oncology BD & Partnering Panel
- Immuno-Oncology Advanced Therapeutics Panel
- Pandemic Response Panel
Day 2 (Thursday, 22nd of September)
- China Strategies Panel
- Global Pharma-Biotech Partnering and M&A Roundtable
- CNS: Focus on Neurodegenerative Diseases Panel
- Therapeutic Session: Autoimmune & Inflammatory Diseases Panel (confirm name)
- Early Stage Investment Panel
- Rising Stars – Seed Companies Session
